13 analysts have expressed a variety of opinions on Jazz Pharmaceuticals JAZZ over the past quarter, offering a diverse set of opinions from bullish to bearish. Summarizing their recent ...

Share price of JAZZ Pharmaceuticals JAZZ hit $102.82 on Tuesday, close to its 52-week low of $99.06. This decline is attributable to the significant downturn in the broader biotech/drug sector due ...

13 analysts have expressed a variety of opinions on Jazz Pharmaceuticals (NASDAQ:JAZZ) over the past quarter, offering a diverse set of opinions from bullish to bearish. Summarizing their recent ...

DUBLIN, March 26, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the 24 th Annual Needham Healthcare Conference. Company ...

Shares of NASDAQ:JAZZ opened at $122.92 on Monday. Jazz Pharmaceuticals plc has a 1 year low of $99.06 and a 1 year high of $148.06. The company has a debt-to-equity ratio of 1.46, a current ratio ...

April 8 (Reuters) - Jazz Pharmaceuticals (JAZZ.O), opens new tab said on Tuesday that it had agreed to a settlement of $145 million to resolve a series of antitrust lawsuits related to its ...

Ahead of a planned trial next month, Jazz Pharmaceuticals is moving to resolve antitrust allegations surrounding its key narcolepsy drug Xyrem with a cool $145 million settlement. Early this week ...

In this article, we are going to take a look at where Jazz Pharmaceuticals plc (NASDAQ:JAZZ) stands against the other best mid cap biotech stocks to buy. On March 6, Jared Holz, Mizuho health care ...

In this article, we are going to look at where Jazz Pharmaceuticals plc (NASDAQ:JAZZ) stands against other biotech stocks. The biotechnology sector is gaining new momentum with better market ...